Antimicrobial coating hospitals rely on is back in the spotlight. New CDC data published this month in the New England Journal of Medicine brought welcome news: healthcare-associated infections (HAIs) in U.S. hospitals fell 27% between 2015 and 2023, with roughly 1 in 38 patients affected today compared to 1 in 31 eight years ago. Central line infections, catheter-associated UTIs, and C. difficile cases are all down significantly — a real win for infection prevention teams nationwide.
But buried in the same dataset is a detail that deserves more attention than it’s getting: 61% of all HAIs recorded were not associated with a device or procedure at all. No catheter, no central line, no surgical site. Pneumonia, gastrointestinal infections, and other cases were simply acquired somewhere in the care environment — likely from contaminated surfaces, high-touch points, or shared equipment. With an estimated 518,000 HAIs still occurring annually in U.S. hospitals, that 61% represents a massive, largely unaddressed exposure pathway.
Why the Environment Still Matters
Hospitals have spent a decade tightening protocols around invasive devices, and it’s paying off. But a hospital room is touched hundreds of times a day — bed rails, door handles, IV poles, monitors, light switches — and standard cleaning only protects a surface until the next contact. Between cleanings, microbial load can rebuild quickly, especially on high-traffic touchpoints that get wiped inconsistently.
This is the gap that residual, between-cleanings surface protection is designed to address — not as a replacement for cleaning and disinfection protocols, but as a supplemental layer that keeps working after the mop and wipe crew has moved on.
Where Supplemental Protection Fits
In the U.S., the EPA classifies this category of product — coatings that provide ongoing, residual antimicrobial activity between standard cleanings — as a Supplemental Residual Antimicrobial Product (SRAP). It’s a distinct category from disinfectants, which kill pathogens at the moment of application but offer no lasting protection.
VireXbuster Spray is built for exactly this role. It’s a hybrid formulation with a very wide spectrum of activity against viruses, bacteria, fungi, mold, and mildew, applied to existing surfaces — metals, plastics, hard and soft substrates alike — and providing protection for up to 12 months per application. It’s already used in hospitals, offices, transport, and other public spaces where high-touch surfaces see constant contact between cleanings.
For facilities managing patient rooms, waiting areas, and shared equipment, that kind of standing protection addresses precisely the non-device exposure pathway the CDC data highlights.
Beyond the Spray: Manufacturing and Walls
Two other angles are worth flagging for facilities and manufacturers thinking longer-term. VireXbuster 4Bulk is an antimicrobial additive mixed directly into plastic pellets during extrusion or injection molding, giving manufactured polymer products — including polymer flooring — years of embedded, built-in protection rather than a surface treatment that needs reapplication. And for walls and ceilings in patient rooms, offices, or clinics, VireXbuster Wall is a waterborne antimicrobial paint that brings the same wide-spectrum protection to painted surfaces (not floors).
VireXbuster is not a disinfectant and doesn’t replace cleaning protocols — it’s a supplemental layer. The formulation itself has been BAuA approved, Fraunhofer tested, QualityLabs certified as antimicrobial, and Dermatest certified “Excellent” for dermatological safety.
Full product details are available at the VireXbuster shop: https://www.virexbuster.de/shop
FAQ
Is VireXbuster a disinfectant? No. VireXbuster is a supplemental residual antimicrobial coating, not a disinfectant. It doesn’t replace routine cleaning and disinfection — it adds a layer of ongoing protection between cleanings by keeping treated surfaces continuously inhospitable to microbial growth.
How does VireXbuster work without revealing a specific chemical formula? VireXbuster uses a hybrid formulation with a very wide spectrum of activity against viruses, bacteria, fungi, mold, and mildew. The exact composition is proprietary, but its performance has been independently verified through Fraunhofer testing and QualityLabs antimicrobial certification.
Can VireXbuster be used on hospital floors? VireXbuster Spray can be applied to a wide range of hard and soft surfaces, and VireXbuster 4Bulk can be manufactured into polymer flooring for embedded, long-term protection. VireXbuster Wall, by contrast, is formulated only for walls and ceilings — not floors.
DaXem GmbH, based in Eschborn, Hessen, Germany, manufactures the VireXbuster line of antimicrobial coatings and additives. Learn more at virexbuster.de/shop.
